Drug development company focused on novel antibiotics for the hospital market. Key program areas for Protez include a breakthrough broad spectrum carbapenem and two combination strategies for product line extensions of multiple established antibiotics. Protez is a portfolio company of Birchmere Ventures III, a joint venture between Birchmere Ventures and Bay City Capital. The company was acquired by Novartis in June 2008.
Protez Pharma
